ClinicalTrials.gg
CompletedNCT02643550Updated May 12, 2023

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

A Phase 1/2 interventional study of Monalizumab and Cetuximab in Head and Neck Neoplasms, sponsored by Innate Pharma. Completed at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-12.

Sponsored by Innate Pharma · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
143
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing cetuximab in Head and Neck Neoplasms — 2 open to participants now, 7 under way, 2 of them phase 3. Cetuximab · Head and Neck Neoplasms.

Enrollment
7th of 84
143 · median 37
Started
2015
with 2 others
Phase 1/2
9 of 86
none open now
Registered
74th of 86
by date

Among the 86 studies testing cetuximab in Head and Neck Neoplasms, this one is the 7th largest by enrollment of the 84 interventional ones that give a count, is one of 3 that started in 2015, is one of 9 in phase 1/2, and was the 74th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

2 of the 86 studies testing cetuximab in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1

03

Conditions studied

  • Head and Neck Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Age ≥ 18 years
  2. or cytologically-confirmed, HPV (+) or HPV (-) squamous cell carcinoma of the nasopharynx (WHO Type 1), oropharynx, hypopharynx, larynx (supraglottis, glottis, subglottis) or oral cavity.
  3. Recurrent or disease, documented by imaging (CT scan, MRI, X-ray) and/or physical examination with as per [RECIST] 1.1

For phase II cohorts:

  • Cohort #1: Patients who received a maximum of two prior systemic regimens for recurrent and/or metastatic disease and not amenable to further therapy with curative intent
  • Cohort #2: Patients with R/M SCCHN not amenable to therapy of curative intent, who have received a maximum of two prior systemic regimens in the R/M setting and who have received prior PD-(L)1 blockers
  • Cohort #3: Patients with R/M SCCHN who have not received prior systemic regimens in the R/M setting and who have not received prior PD-(L)1 inhibitors

Main Exclusion Criteria:

  1. For phase II cohort #1 and cohort #2: Patients who received more than 2 prior systemic regimens for recurrent and/or metastatic disease (no restriction in the phase Ib part of the trial).
  2. For phase II cohort #1 and cohort #2: Patients who received cetuximab or another inhibitor of epidermal growth factor receptor are excluded from the phase II of the trial, except if cetuximab was given as part of a primary treatment approach, with no progressive disease for at least 4 months following the end of prior cetuximab treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Dose escalation

    Dose escalation of monalizumab in combination with cetuximab

    Biological: Monalizumab · Biological: Cetuximab

  • Experimental
    Expansion cohort 1

    monalizumab + cetuximab expansion cohort

    Biological: Monalizumab · Biological: Cetuximab

  • Experimental
    Expansion cohort 2

    monalizumab + cetuximab expansion cohort in patients with prior exposure to PD-(L)1 blockers

    Biological: Monalizumab · Biological: Cetuximab

  • Experimental
    Expansion cohort 3

    monalizumab + cetuximab + anti-PD(L)1

    Biological: Monalizumab · Biological: Cetuximab · Biological: Anti-PD(L)1

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of Dose Limiting Toxicities (DLT) in the dose escalation part of the study

    To assess the occurrence of Drug Limited Toxicities (DLTs)

    Time frame: within 4 weeks after first administration

  2. Objective Response Rate for expansion cohorts

    rate of patients in complete or partial response according to RECIST 1.1.

    Time frame: up to 12 months

Secondary outcomes

  1. Objective Response Rate for dose escalation part of the study

    rate of patients in complete or partial response according to RECIST 1.1

    Time frame: up to 12 months

  2. Duration of Response for expansion cohorts

    Duration of complete and partial response

    Time frame: From confirmed response until disease progression, up to 12 months

  3. Progression Free Survival for expansion cohorts

    time between the start of treatment and the first documented progression or death

    Time frame: Until disease progression or death, up to 2 years

  4. Overall Survival for expansion cohorts

    time between the start of treatment and death

    Time frame: Until death, up to 2 years

07

Study locations

18 sites
  • University of California, Moores Cancer Center
    La Jolla, California, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Maryland, Greenebaum Comprehensive Cancer Center
    Baltimore, Maryland, United States
  • Washington University School of Medicine
    Saint Louis, Missouri, United States
  • Icahn School of Medicine at Mount Sinaï
    New York, New York 10029, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
  • Centre Jean Perrin
    Clermont-Ferrand, France
  • Centre Oscar Lambret
    Lille, France
  • Centre Leon Berard
    Lyon, France
  • Hopital La Timone
    Marseille, France
  • Institut Regional du Cancer de Montpellier
    Montpellier, France
  • Centre Antoine Lacassagne
    Nice, France
  • Centre Eugene Marquis
    Rennes, France
  • ICO Rene Gauducheau
    Saint-Herblain, France
  • Institut Gustave Roussy
    Villejuif, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Mar 2023 and a completion of Mar 2023. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2015
First posted
Dec 31, 2015
Start
Dec 2015
Primary completionActual
Mar 28, 2023
CompletionActual
Mar 28, 2023
Last update
May 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02643550
Lead sponsor
Innate Pharma
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Dec 31, 2015
Start date
Dec 2015
Primary completion
Mar 28, 2023
Completion
Mar 28, 2023
Last update
May 12, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Monalizumab · Cetuximab

Start the discussion